Your source for all Prime Therapeutics' December 2024 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for December 2024 will keep you informed on what’s trending now.

Released Jan. 13, 2025

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are prademagene zamikeracel/ (Abeona) and pariglasgene brecaparvovec / (Ultragenyx).

High Cost Therapy Profile

Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features Tabelecleucel Intravenous (IV) for Epstein-Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD).